Patents Issued in March 21, 2024
  • ORAL BILAYER TABLETS COMPRISING ACETYLSALICYLIC ACID AND PSEUDOEPHEDRINE, METHODS OF PREPARING AND USING THEREOF
    Publication number: 20240091158
    Abstract: The present disclosure relates generally to bilayer tablets comprising a combination of two active pharmaceutical ingredients, and more specifically to bilayer tablets comprising acetylsalicylic acid, pseudoephedrine, and a dissolution aid. The bilayer tablets utilize a combination of granulated and non-granulated acetylsalicylic acid along with a unique distribution of sodium carbonate as a dissolution aid that provide acetylsalicylic acid and pseudoephedrine in a single dosage form having rapid dissolution and long-term storage stability (low degradation). The present disclosure also provides methods of preparing and of using the bilayer tablets.
    Type: Application
    Filed: June 22, 2023
    Publication date: March 21, 2024
    Applicant: Bayer HealthCare LLC
    Inventor: Harsh MEHTA
  • Combination and Uses and Treatments Thereof
    Publication number: 20240091159
    Abstract: Methods are provided for treating or preventing human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) in a virologically suppressed patient in need thereof comprising switching the patient from an antiretroviral treatment regimen comprising at least three antiretroviral agents to a treatment regimen comprising only two antiretroviral agents. In one aspect the two treatment regimen consists of dolutegravir, rilpivirine and at least one pharmaceutically acceptable excipient, diluent or carrier. In another aspect of the invention, there is provided a multilayer tablet comprising dolutegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 7, 2023
    Publication date: March 21, 2024
    Applicants: ViiV Healthcare Company, Janssen Sciences Ireland Unlimited Company
    Inventors: Kenneth Churchill CAMPBELL, Urbain Alfons C. DELAET, James M. GOODRICH, Juliette Segolène GUAQUIÈRE, Thomas LAUGHERY, Dominique J. LIMET, John C. POTTAGE, Ludovic Sylvain Marc RENOU, Trevor R. SCOTT, Christian SEILER, Mary WOODWARD
  • PHARMACEUTICAL COMPOSTION CONTAINING ACETOMINOPHEN AND IBUPROFEN
    Publication number: 20240091160
    Abstract: Solid oral dosage forms containing 325 mg of acetaminophen and 97.5 mg of ibuprofen or 500 mg of acetaminophen and 150 mg of ibuprofen, wherein the ibuprofen has a [D50] between 1 and 9 ?m, are described.
    Type: Application
    Filed: November 22, 2023
    Publication date: March 21, 2024
    Inventors: Maura Murphy, Matt Callahan
  • NON-ANIMAL SOFTGEL CAPSULE FORMULATIONS, METHODS OF PREPARATION, AND METHODS OF USE THEREOF
    Publication number: 20240091161
    Abstract: Disclosed in certain embodiments is a softgel composition comprising a fill material encapsulated in a shell composition. The shell composition having a non-animal derived gelling agent and a water soluble polymer. The shell composition completely dissolving in less than 30 minutes when subject to a dissolution with a USP Apparatus II with paddies at 75 RPM in 900 ml of 0.1N HCL and deionized water at 37 degrees C.
    Type: Application
    Filed: October 8, 2020
    Publication date: March 21, 2024
    Inventors: Qi Fang, Keith Tanner, Karunakar Sukuru, Aristippos Gennadios
  • COMPOSITIONS AND METHODS FOR TREATING DEPRESSION AND ANXIETY
    Publication number: 20240091162
    Abstract: The present disclosure provides, inter alia, compositions and methods for treating or ameliorating the effect of a disorder such as, e.g., anxiety or depression in a subject, with less or no off- and/or on-target side effects. Also provided are methods for treating such disorder in a pregnant woman.
    Type: Application
    Filed: November 20, 2023
    Publication date: March 21, 2024
    Inventors: Kara MARGOLIS, Mark ANSORGE, Kam W. LEONG, Letao YANG, Yuefei ZHU
  • SUSTAINED RELEASING PARTICLE AND METHOD OF PRODUCING SUSTAINED RELEASING PARTICLE
    Publication number: 20240091163
    Abstract: A sustained releasing particle contains a water-soluble physiologically active substance and a fat-soluble base material, wherein the sustained releasing particle has a ratio of a surface area to a volume is 0.6 or less.
    Type: Application
    Filed: September 7, 2023
    Publication date: March 21, 2024
    Applicant: Ricoh Company, Ltd.
    Inventors: Yuichi Sato, Ryota Inoue, Tatsuru Moritani
  • SURFACE COATING PPSU NANOPARTICLES FOR THERAPEUTIC MODULATION OF MAST CELLS
    Publication number: 20240091164
    Abstract: The present disclosure provides methods of adsorbing proteins to the surface of a nanoparticle. Particularly, methods for adsorbing anti-Siglec-6 and anti-Fc?RI antibodies to PPSU nanoparticles, are described. The disclosure further provides compositions comprising the nanoparticles are methods of their use to prevent mast cell secretion and anaphylaxis.
    Type: Application
    Filed: September 8, 2023
    Publication date: March 21, 2024
    Inventors: Evan Alexander Scott, Bruce Scott Bochner, Clayton Hunter Rische
  • MELT PROCESSED VIRAL NANOPARTICLE CONSTRUCTS
    Publication number: 20240091165
    Abstract: A melt processed viral nanoparticle construct for delivery of virus or virus-like particles to a site of interest includes a degradable polymer matrix and a plurality of virus or virus-like particles encapsulated within the degradable polymer matrix. The nanoparticle construct upon administration to the site of interest providing a sustained release of the virus or virus-like particles and/or nanoparticles upon degradation of the polymer matrix.
    Type: Application
    Filed: May 23, 2023
    Publication date: March 21, 2024
    Inventors: Nicole F. Steinmetz, Jonathan Pokorski
  • APPARATUS AND PROCESS FOR PRODUCING NANOCARRIERS AND/OR NANOFORMULATIONS
    Publication number: 20240091166
    Abstract: An apparatus and corresponding process can be used for producing nanocarriers and or nanoformulations and corresponding process products. The apparatus is characterized by a vertical orientation of the feed conduits leading to active element. The feed conduits are nested within one another and are axially movable in terms of their orientation to one another. The process provides for the mixing of at least two liquid phases with different acidities. The volume flow of the first phase is greater than that of the second phase.
    Type: Application
    Filed: March 8, 2022
    Publication date: March 21, 2024
    Applicant: Evonik Operations GmbH
    Inventors: Mario GOMEZ, Jürgen Erwin Lang, Marcel Arndt
  • USE OF TWO-DIMENSIONAL NANOMATERIAL IN INHIBITION OF CORONAVIRUS
    Publication number: 20240091167
    Abstract: Provided is the use of two-dimensional nanomaterials in the inhibition of a coronavirus, and specifically disclosed is the use of the two-dimensional nanomaterials in the preparation of a medicament for treating or preventing diseases caused by a coronavirus or of a material for adhering to or inhibiting the coronavirus. The two-dimensional nanomaterial is selected from the group consisting of copper indium thiophosphate (CIPS) nanosheet, graphene oxide nanosheet, molybdenum disulfide nanosheet, black phosphorus nanosheet and mixtures thereof. The coronavirus is selected from one of HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, SARS-CoV2 or MERS-CoV. The diseases caused by the coronavirus are diseases caused by coronavirus infection. The material has the advantages of being simple to prepare, having a high biological safety and an excellent effect.
    Type: Application
    Filed: December 22, 2021
    Publication date: March 21, 2024
    Applicants: SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY, INSTITUTE OF HIGH ENERGY PHYSICS, CAS
    Inventors: Yang LI, Liming WANG, Guofang ZHANG
  • SYSTEMS AND METHODS FOR LONG TERM TRANSDERMAL ADMINISTRATION
    Publication number: 20240091168
    Abstract: Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.
    Type: Application
    Filed: April 4, 2023
    Publication date: March 21, 2024
    Inventors: Eun Soo LEE, Amit K. JAIN, Parminder SINGH
  • POLYACETYLENE COMPOUNDS FOR TREATING INFLAMMATORY DISEASES
    Publication number: 20240091169
    Abstract: In general, disclosed herein are methods of treating an inflammatory disease or disorder by administering to the subject in need thereof a polyacetylene compound. The polyacetylene compound may be administered at a dose of from about 1 mg/kg body weight to about 10 mg/kg body weight.
    Type: Application
    Filed: August 24, 2023
    Publication date: March 21, 2024
    Inventors: ELIZABETH A. MURPHY, LORNE HOFSETH
  • Catechol Nanoparticle, Catechol Protein Nanoparticle, and Preparation Method and Use Thereof
    Publication number: 20240091170
    Abstract: Provided are catechol nanoparticles, catechol protein nanoparticles, and a preparation method and use thereof. The method includes: adding a tannin compound-containing natural herb medicine into water to obtain a mixture, and subjecting the mixture to heating reflux extraction to obtain a herb medicine extract and subjecting the herb medicine extract to fractionation to obtain the catechol nanoparticles.
    Type: Application
    Filed: August 1, 2023
    Publication date: March 21, 2024
    Applicant: Shihezi University
    Inventors: Bo HAN, Jingmin Fan, Hang Yu, Rui Xue, Jiawei Guan, Yu Xu, Linyun He, Ji Liu, Chengyu Jiang, Xin Lu, Xiangze Kong, Wei Yu, Wen Chen
  • DERMATOLOGICAL COMPOSITIONS AND USES THEREOF
    Publication number: 20240091171
    Abstract: Methods for treating or preventing microbial infection, methods for treating or preventing a dermatological condition caused by environmental or pathological factors, and compositions for use in such methods are disclosed.
    Type: Application
    Filed: April 14, 2023
    Publication date: March 21, 2024
    Inventor: Reza Babapour
  • DRUG FOR ANTAGONIZING REPLICATION OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND APPLICATION THEREOF
    Publication number: 20240091172
    Abstract: A drug for antagonizing the replication of porcine reproductive and respiratory syndrome virus (PRRSV) and an application thereof. By using a viral infection test, a drug which antagonizes PRRSV—xanthohumol—is discovered for the first time from among a natural drug library of 386 plant sources. Xanthohumol can effectively inhibit PRRSV replication on both Marc-145 and PAM cells. Five xanthohumol derivatives having different molecular structures are artificially synthesized, and it is discovered that a derivative Xn-4 has the strongest inhibitory effect on virus replication in vitro. Test results of artificial infection and drug therapy in piglets show that the Xn-4 can effectively inhibit PRRSV viremia, relieve clinical symptoms of infected pigs, and significantly reduce lung inflammation and pathological damage.
    Type: Application
    Filed: June 3, 2020
    Publication date: March 21, 2024
    Applicant: NANJING AGRICULTURAL UNIVERSITY
    Inventors: Ping JIANG, Xuewei LIU, Juan BAI, Junren ZHANG, Xianwei WANG, Yufeng LI
  • COMMON COLD SYMPTOM RELIEVING AGENT
    Publication number: 20240091173
    Abstract: To reveal which curcumin preparation, among various existing curcumin preparations, is effective for various symptoms of a common cold. Provided is an agent for relieving common cold symptom which contains, as an active ingredient, a curcumin-containing composition that contains fine particles of curcumin or turmeric pigment, or a mixture containing curcumin or turmeric pigment containing an amorphous thereof and a cellulose derivative.
    Type: Application
    Filed: December 6, 2022
    Publication date: March 21, 2024
    Applicant: THERAVALUES CORPORATION
    Inventor: Yoshitaka KUWABARA
  • Method Of Treating Major Depressive Disorder
    Publication number: 20240091174
    Abstract: The present invention provides a method for safe and efficacious administration of esketamine.
    Type: Application
    Filed: November 22, 2023
    Publication date: March 21, 2024
    Inventors: Elena Kagan, Gina Pastino
  • METHODS OF CONTROLLING MYOCARDIAL BLOOD FLOW
    Publication number: 20240091175
    Abstract: In certain embodiments, the present invention provides a method of modulating myocardial blood flow (MBF) as compared to a control in a patient in need thereof, comprising administering an agent that interacts with a Kv? protein.
    Type: Application
    Filed: September 20, 2023
    Publication date: March 21, 2024
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Matthew Nystoriak, Aruni Bhatnagar
  • EPINEPHRINE FORMULATIONS
    Publication number: 20240091176
    Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.
    Type: Application
    Filed: September 19, 2023
    Publication date: March 21, 2024
    Inventors: Suketu Sanghvi, Vinayagam Kannan, Matthew Kenney
  • METHODS FOR TREATING CANCER
    Publication number: 20240091177
    Abstract: Disclosed herein are methods of treating one or more tumors by administering to the subject a therapeutically effective amount of a combination of RAD1901 or solvates (e.g., hydrate) or salts thereof and one or more second therapeutic agent(s) (e.g., everolimus). The cancer is an estrogen-dependent cancer, such as breast cancer, ovarian cancer, colon cancer, endometrial cancer, or prostate cancer.
    Type: Application
    Filed: November 16, 2023
    Publication date: March 21, 2024
    Inventor: Gary HATTERSLEY
  • METHOD OF TREATING A PERSON AFFLICTED WITH A RESPIRATORY CONDITION AND PHARMACEUTICAL FORMULATION INCLUDING DAPSONE
    Publication number: 20240091178
    Abstract: A method for treating patients with COVID-19 and/or other respiratory conditions includes administering eighty-five milligrams of dapsone twice daily for twenty-one days. A variety of dapsone formulations and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.
    Type: Application
    Filed: November 27, 2023
    Publication date: March 21, 2024
    Inventors: Houfar SEKHAVAT, Satish ASOTRA
  • OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
    Publication number: 20240091179
    Abstract: Provided herein are ophthalmic pharmaceutical compositions comprising (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide (WS-12) for effectively treating dry eye in a subject in need thereof, effectively reducing dry eye in a subject in need thereof, effectively reducing the likelihood of dry eye in a subject in need thereof, or for treating, preventing, or ameliorating signs or symptoms of dry eye in a subject in need thereof.
    Type: Application
    Filed: November 15, 2023
    Publication date: March 21, 2024
    Inventor: Anjali Joshi
  • METHODS OF TREATMENT OF CHOLESTATIC DISEASES
    Publication number: 20240091180
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5 -dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Application
    Filed: November 9, 2023
    Publication date: March 21, 2024
    Inventor: Remy Hanf
  • CANCER TREATMENT COMPOSITION AND METHOD
    Publication number: 20240091181
    Abstract: A method for selectively or preferentially reducing the amount of Fe ions available to cancer cells involves introducing to an area of the body which contains cancer cells an effective amount of an aqueous, pH buffered composition that includes dissociation products of a soluble weak acid and a salt of a weak acid. When the amount of arriving Fe ions falls below a first threshold, the cancer cell no longer can proliferate. When the amount of arriving Fe ions falls below a second threshold, the cancer cell dies.
    Type: Application
    Filed: December 28, 2021
    Publication date: March 21, 2024
    Applicant: Next Science IP Holdings Pty Ltd
    Inventor: Matthew F. Myntti
  • LOW DOSE, SUSTAINED RELEASE FORMULATION FOR ALLEVIATING SYMPTOMS CAUSED BY INCREASED LEVELS OF DOPAMINE AND NOREPINEPHRINE
    Publication number: 20240091182
    Abstract: Detailed herein are formulation(s) for alleviating symptoms of autism spectrum disorder as well as other indications. In at least one embodiment, there is described a low dose, sustained release formulation comprising alpha-methyl-L-tyrosine (AMT or AMPT). Such a low dose, sustained release formulation provides a less regimented treatment regimen as well as minimizes potential adverse side effects.
    Type: Application
    Filed: September 18, 2023
    Publication date: March 21, 2024
    Inventor: Francis Peter Halas
  • TREATMENT REGIMENS WITH FIXED DOSES OF TAMIBAROTENE
    Publication number: 20240091183
    Abstract: The present invention features, inter alia, methods of treating (a) a patient who has been diagnosed with a hematopoietic cancer or (b) a population of patients who have been diagnosed with a hematopoietic cancer with a fixed dose of tamibarotene or a pharmaceutically acceptable salt thereof. The tamibarotene is administered daily, for a prescribed number of days, at 8-14 (e.g., 12 mg/day) regardless of the patient's weight or body surface area, and may be administered as the sole therapeutic agent or in combination with one or more of the additional therapeutic agents described herein.
    Type: Application
    Filed: January 7, 2022
    Publication date: March 21, 2024
    Inventors: David A. Roth, Michael J. Kelly, Catherine E. Madigan, Maria Rosario
  • MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF
    Publication number: 20240091184
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: May 1, 2023
    Publication date: March 21, 2024
    Inventors: Eddine SAIAH, George VLASUK
  • COMPOSITION FOR IMPROVING COGNITIVE FUNCTION, AGENT FOR IMPROVING COGNITIVE FUNCTION, AND FOOD FOR IMPROVING COGNITIVE FUNCTION
    Publication number: 20240091185
    Abstract: Compositions, containing glycine and serine and having a content ratio of glycine to serine (glycine/serine) of not less than 0.6 in weight ratio are effective for improving cognitive function, and have an effective preventive or improving effect on a decline in cognitive function and cognitive dysfunction, are highly safe, and enable continuous ingestion or administration.
    Type: Application
    Filed: November 20, 2023
    Publication date: March 21, 2024
    Applicant: AJINOMOTO CO., INC.
    Inventors: Hidehiro NAKAMURA, Noriko KAWASAKI, Yasuko KAWAMATA, Akihiko KITAMURA, Ryosei SAKAI, Fumika TAKEUCHI
  • COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR
    Publication number: 20240091186
    Abstract: A composition can treat or prevent at least one physical state selected from the group consisting of oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, and a condition associated with a reduced level of glutathione. The composition contains an effective amount of a combination of at least one glycine or functional derivative thereof, at least one N-acetylcysteine or functional derivative thereof, and at least one nicotinamide riboside or NAD+ precursor. The composition can be orally administered, for example as one or more of a food product, a food for special medical purposes (FSMP), a nutritional supplement, a ready to drink formula, a dairy-based drink, a low-volume liquid supplement, powder formats for liquid reconstitution or a meal replacement beverage.
    Type: Application
    Filed: November 27, 2023
    Publication date: March 21, 2024
    Inventors: Philipp Gut, Stephanie Blum-Sperisen, Giulia Lizzo
  • PHARMACEUTICAL COMPOSITIONS OF D10-DOCOSAHEXAENOIC ACID OR ESTERS THEREOF
    Publication number: 20240091187
    Abstract: Disclosed are methods for assessing the presence or absence of a therapeutic concentration of a deuterated docosahexaenoic acid during treatment of a patient with a retinal or neuronal oxidative disease.
    Type: Application
    Filed: February 10, 2023
    Publication date: March 21, 2024
    Inventors: Karsten SCHMIDT, Mikhail SHCHEPINOV
  • Dosing Protocols for Administering Deuterated Arachidonic Acid or a Prodrug Thereof
    Publication number: 20240091188
    Abstract: Disclosed are methods or dosing protocols for administering deuterated arachidonic acid or a prodrug thereof to a patient in order to accelerate the time required to achieve of a therapeutic concentration of 13,13-D2-arachidonic acid in vivo.
    Type: Application
    Filed: February 4, 2022
    Publication date: March 21, 2024
    Applicant: Retrotope, Inc.
    Inventors: Peter Milner, Mikhail Sergeevich Shchepinov
  • Methods for Assessing a Patient's Response to Treatment of a Neurodegenerative Disease with Deuterated Arachidonic Acid
    Publication number: 20240091189
    Abstract: Disclosed are diagnostic methods for assessing the presence or absence of a therapeutic concentration of a deuterated polyunsaturated fatty acid in diseased neurons during treatment of a patient with a neurodegenerative disease.
    Type: Application
    Filed: February 4, 2022
    Publication date: March 21, 2024
    Inventors: Peter Milner, Mikhail Sergeevich Shchepinov
  • SKIN CREAM FOR REDUCING BED SORES
    Publication number: 20240091190
    Abstract: A composition for external use that is used to heal and prevent wounds is described. The composition is used to prevent bedsores. The composition includes a thickening agent, an anti-fungal agent, an emulsifier, a glycerol, a skin protectant, a petroleum jelly, an oil, and at least one vitamin.
    Type: Application
    Filed: September 16, 2022
    Publication date: March 21, 2024
    Inventor: Elsia Kelly
  • USES OF CORYLIN AND/OR NEOBAVAISOFLAVONE IN TREATING SYMPTOMS ASSOCIATED WITH SENESCENCE
    Publication number: 20240091191
    Abstract: Disclosed herein is related to a method for treating a symptom associated with senescence in a subject by administering to the subject with an effective amount of corylin and/or neobavaisoflavone, wherein the symptom associated with senescence is loss of muscle strength, muscle weakness, loss of motor coordination, loss of balance, skin wrinkle, or a poor blood biochemical parameter.
    Type: Application
    Filed: September 2, 2022
    Publication date: March 21, 2024
    Applicant: Chang Gung University
    Inventors: Chin-Chuan CHEN, Yann-Lii LEU, Shu-Huei WANG, Tong-Hong WANG, Shu-Fang CHENG
  • DILUTABLE FORMULATIONS OF CANNABINOIDS AND PROCESSES FOR THEIR PREPARATION
    Publication number: 20240091192
    Abstract: Cannabinoid-loaded formulations are characterized by including 0.5 wt. % to 20 wt. % medium chain triglycerides, one or more hydrophilic surfactants, one or more co-surfactants and 0.1 wt. % or more of at least one cannabinoid. The formulations are in microemulsion form, and are fully dilutable by an aqueous diluent.
    Type: Application
    Filed: October 12, 2023
    Publication date: March 21, 2024
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Nissim GARTI, Sharon GARTI LEVI, Rotem EDRI
  • ANTI-SENESCENCE PLANT POLYPHENOL DRUG DOWNREGULATING SENESCENCE-RELATED SECRETORY PHENOTYPE AND USE THEREOF
    Publication number: 20240091193
    Abstract: Disclosed is a pharmaceutical composition containing (a) procyanidine or pharmaceutically acceptable salt, hydrate or prodrug thereof, and (b) a reagent capable of inducing an object to generate senescent cells, and optionally, a pharmaceutically acceptable excipient.
    Type: Application
    Filed: February 23, 2021
    Publication date: March 21, 2024
    Inventors: Yu SUN, Qixia XU, Xuguang ZHANG, Ruikun HE
  • 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-Yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid For Use In Metastatic Or Advanced Breast Cancer Patients
    Publication number: 20240091194
    Abstract: The compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, for use in the treatment of metastatic or advanced breast cancer at a dose of 150 to 600 mg per day.
    Type: Application
    Filed: September 1, 2023
    Publication date: March 21, 2024
    Applicant: Sanofi
    Inventors: Sylvaine CARTOT-COTTON, Marina CELANOVIC, Patrick COHEN, Gautier PAUX, Sandrine Anneheim-Herbelin
  • MEDICINE COMPRISING GLYCOPYRRONIUM SALICYLATE
    Publication number: 20240091195
    Abstract: A medicine includes glycopyrronium salicylate or a solvate thereof, wherein the medicine is used for treating or preventing sialorrhea and the like. A therapeutic drug enables the treatment of sialorrhea by affixing and a novel salt of glycopyrronium is suitable for a transdermal absorptive preparation.
    Type: Application
    Filed: February 4, 2022
    Publication date: March 21, 2024
    Applicant: SANWA KAGAKU KENKYUSHO CO., LTD.
    Inventors: Kazuhiro UECHI, Masao SAKAIRI, Sou SUGITANI, Nobutaka MORIMOTO, Kazuki TAKADA, Takehiko NAKAMURA
  • USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCER
    Publication number: 20240091196
    Abstract: IT-139, sodium trans-[tetrachlorobis(lH-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from 1T-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemo-therapy and immuno-oncology agents to be more effective in treating cancer.
    Type: Application
    Filed: April 19, 2023
    Publication date: March 21, 2024
    Inventors: Suzanne BAKEWELL, Jyothi SETHURAMAN
  • TREATMENTS WITH NIROGACESTAT
    Publication number: 20240091197
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Application
    Filed: October 20, 2023
    Publication date: March 21, 2024
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • AQUEOUS COMPOSITION COMPRISING DANTROLENE
    Publication number: 20240091198
    Abstract: The present invention relates to an aqueous composition comprising either dantrolene or a pharmaceutically acceptable salt thereof and a cyclodextrin derivative wherein the pH of the aqueous composition is greater than 7. Further, the present invention relates to a powder obtained by drying the inventive composition as well as a kit comprising said inventive powder.
    Type: Application
    Filed: November 7, 2023
    Publication date: March 21, 2024
    Applicant: SPEPHARM AG
    Inventors: Hervé Jean SCHWEBEL, Vincent ADAMO
  • Deuterated Domperidone Compositions, Methods, and Preparation
    Publication number: 20240091199
    Abstract: Deuterated domperidone compositions, methods of synthesis, methods of use, and dosing formulations providing beneficial safety and other effects.
    Type: Application
    Filed: June 20, 2022
    Publication date: March 21, 2024
    Applicant: CinDome Pharma, Inc.
    Inventors: Catherine PEARCE, Jon ISAACSOHN, Piyush PATEL
  • Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors
    Publication number: 20240091200
    Abstract: The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.
    Type: Application
    Filed: September 27, 2023
    Publication date: March 21, 2024
    Inventors: Hongyan Guo, Amy S. Lee, Hyung-Jung Pyun, Devleena M. Shivakumar, Manoj C. Desai, Lianhong Xu, John E. Knox, Zachary ER Newby
  • FORMULATIONS OF DEFERASIROX AND METHODS OF MAKING THE SAME
    Publication number: 20240091201
    Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
    Type: Application
    Filed: November 24, 2023
    Publication date: March 21, 2024
    Applicant: AustinPx, LLC
    Inventors: Dave A. MILLER, Justin M. KEEN, Sandra U. KUCERA
  • COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS
    Publication number: 20240091202
    Abstract: The invention relates to the treatment and prevention of diseases and conditions associated with EBV infection. In particular, the invention is directed to the use of an IDO1 inhibitor for the treatment and prevention of diseases and conditions associated with EBV infection. The invention also relates to methods for predicting the risk of developing a disease or condition associated with EBV infection.
    Type: Application
    Filed: March 4, 2022
    Publication date: March 21, 2024
    Inventors: Christoph HESS, Bojana MÜLLER-DUROVIC, Glenn BANTUG
  • METHODS FOR TREATING NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
    Publication number: 20240091203
    Abstract: Methods for treating non-obstructive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with mid-ventricular obstruction (MVO) are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administrated daily dose based on a component of an echocardiogram. The daily dose may be increased, maintained, or decreased, or terminated, based on the echocardiogram.
    Type: Application
    Filed: July 19, 2023
    Publication date: March 21, 2024
    Inventors: Stephen B. HEITNER, Fady MALIK, Stuart KUPFER, Daniel Louis JACOBY
  • MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE
    Publication number: 20240091204
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of ?-synuclein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon. Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Application
    Filed: September 18, 2023
    Publication date: March 21, 2024
    Inventors: Andrew P. Crew, Hanqing Dong, Michael Berlin, Steven M. Sparks
  • PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE
    Publication number: 20240091205
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Application
    Filed: July 29, 2023
    Publication date: March 21, 2024
    Inventors: Jay Edward WROBEL, Allen B. REITZ, Jeffery Claude PELLETIER, Garry Robert SMITH, Haiyan BIAN
  • COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA
    Publication number: 20240091206
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Application
    Filed: November 22, 2023
    Publication date: March 21, 2024
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • COMPOSITIONS AND METHODS FOR STORAGE STABLE OPHTHALMIC DRUGS
    Publication number: 20240091207
    Abstract: The present invention is related to methods of stabilizing an ophthalmic drug by adding a surfactant and a viscosity enhancer to the ophthalmic drug to create a composition wherein the composition has a viscosity of about 25 centipoise or less at a shear rate of 1/1000 per second at 25 degrees Celsius and a viscosity of about 70 centipoise or more at shear rate of 1 per second at 25 degrees Celsius, filling the composition into a container; and storing the container at a temperature from about 2 degrees Celsius to about 25 degrees Celsius. The present invention is further directed to a container prepared by the methods of the present invention.
    Type: Application
    Filed: September 18, 2023
    Publication date: March 21, 2024
    Inventor: Gerald HORN